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Abstract
The mode of the antitumoral activity of multimutated
oncolytic herpes simplex virus type 1 G207 has not
been fully elucidated yet. Because the antitumoral
activity of many drugs involves the inhibition of tumor
blood vessel formation, we determined if G207 had
an influence on angiogenesis. Monolayers of human
umbilical vein endothelial cells and human dermal
microvascular endothelial cells, but not human dermal
fibroblasts, bronchial epithelial cells, and retinal glial
cells, were highly sensitive to the replicative and
cytotoxic effects of G207. Moreover, G207 infection
caused the destruction of endothelial cell tubes in vitro.
In the in vivo Matrigel plug assay in mice, G207
suppressed the formation of perfused vessels. Intra-
tumoral treatment of established human rhabdomyo-
sarcoma xenografts with G207 led to the destruction
of tumor vessels and tumor regression. Ultrastructural
investigations revealed the presence of viral particles
in both tumor and endothelial cells of G207-treated
xenografts, but not in adjacent normal tissues. These
findings show that G207 may suppress tumor growth,
in part, due to inhibition of angiogenesis.
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Introduction
Viruses used for oncolytic therapy replicate selectively in
transformed cells, killing them through a direct cytopathic
effect and enabling the viral progeny to spread within the
tumor, sparing nontransformed surrounding cells [1]. Her-
pes simplex virus type 1 (HSV-1) G207 was initially
designed for clinical use in malignant brain tumor patients.
Experimental studies demonstrated its efficiency also
against human carcinoma cell lines of the breast [2], pros-
tate [3], colon [4], ovaries [5], head and neck squamous
cells [6], malignant melanoma [7], as well as pediatric solid
tumors such as neuroblastoma [8,9], rhabdomyosarcoma
[10,11], and osteosarcoma [10]. G207 harbors deletions in
both copies of the c34.5 gene, the major determinant of HSV-1
neurovirulence [12,13], and carries an insertion of the Escher-
ichia coli lacZ gene in the viral ICP6 gene (UL39), inactivating
viral ribonucleotide reductase (RR) [14]. Because viral replica-
tion can only take place in the presence of RR, replication of
G207 is limited to dividing cells expressing high levels of
cellular RR [15,16]. Insertion of a lacZ marker gene, which
produces a histochemically identifiable protein product, ena-
bles easy detection of virus-infected cells [17]. The multiple
mutations of HSV-1 G207 minimize the chance of reversion to
wild-type virus and confer additional safety features such as
sensitivity to ganciclovir and temperature sensitivity, which
halts viral activity in the febrile host [17,18].
In the past decades, increased interest has been focusing
on the role of new blood vessel formation in the pathogenesis
of tumors [19,20]. In addition to specific antiangiogenic agents,
virtually every conventional cytotoxic anticancer drug has been
‘‘accidentally’’ discovered to have antiangiogenic effects in
various in vivo models [21,22]. In the present study, we tested
the sensitivity of endothelial cells to G207 and the ability of
the virus to inhibit angiogenesis in vitro and in vivo.
Materials and Methods
Virus
G207 was kindly provided by NeuroVir (Vancouver,
Canada). The wild type of HSV-1 (strain McIntyre) was
purchased from ATCC (Manassas, VA). Viral stocks were
prepared by infecting African green monkey kidney cells (Vero;
Abbreviations: HSV-1, herpes simplex virus type 1; HUVEC, human umbilical vein endothelial
cells; HDMEC, human dermal microvascular endothelial cells; HRG, retinal glial cells; NHBE,
normal human bronchial epithelial cells; RR, ribonucleotide reductase; IMDM, Iscove’s
modified Dulbecco’s medium; bFGF, basic fibroblast growth factor; MEM, minimal essential
medium; MOI, multiplicity of infection; X-gal, 5-bromo-4-chloro-3-indolyl-h-D-galactopyrano-
side; PFU, plaque-forming units
Address all correspondence to: Jindrich Cinatl, Jr., PhD, Institute of Medical Virology,
Center of Hygiene, Paul-Ehrlich Str., 40, Frankfurt am Main D-60596, Germany.
E-mail: Cinatl@em.uni-frankfurt.de
1This work was generously supported by the friendly society ‘‘Hilfe fu¨r krebskranke Kinder
Frankfurt eV’’ and its foundation ‘‘Frankfurter Stiftung fu¨r krebskranke Kinder.’’
2Martin Michaelis and Pablo Herna´iz Driever equally contributed to this paper.
Received 2 April 2004; Revised 10 June 2004; Accepted 18 June 2004.
Copyright D 2004 Neoplasia Press, Inc. All rights reserved 1522-8002/04/$25.00
DOI 10.1593/neo.04265
Neoplasia . Vol. 6, No. 6, November/December 2004, pp. 725–735 725
www.neoplasia.com
RESEARCH ARTICLE
ATCC) cultured in MEM supplemented with 5% inactivated
fetal calf serum (FCS) at a multiplicity of infection (MOI) of
0.01 at 34jC and by harvesting the virus when a complete
cytopathic effect was observed. After a freeze–thaw/soni-
cation regime, cell debris was removed by low-speed cen-
trifugation (2000g for 10 minutes at 4jC). G207 was
concentrated by subsequent high-speed centrifugation
(45,000g for 150 minutes at 4jC). The viral pellet was then
resuspended in 150 mM NaCl and 20 mM Tris, pH 7.5.
Infectious titers of viral stocks were determined by plaque
titration on Vero cell monolayers as described previously [11]
and stored at 80jC before use.
To investigate whether antiangiogenic effects of G207
were attributed to viral replication, inactivated G207 was
used as a control. Inactivation of the virus was achieved by
the exposure of viral solution to UVB light (280–350 nm,
peak at 306 nm) for 25 minutes, delivering approximately
3.6 J/cm2. UV-irradiated virus suspensions were free of
infectious virus as demonstrated by plaque titration using
Vero cell monolayers.
Cells
Human umbilical vein endothelial cells (HUVEC) were
isolated and cultured in Iscove’s modified Dulbecco’s medi-
um (IMDM; Sigma, Taufkirchen, Germany) supplemented
with 10% FCS, 10% pooled human serum (Blood Bank of
the German Red Cross, Frankfurt am Main, Germany),
100 IU/ml penicillin, 100 mg/ml streptomycin, and 5 ng/ml
basic fibroblast growth factor (bFGF), as described previ-
ously [23]. Human dermal microvascular endothelial cells
(HDMEC) were obtained from PromoCell (Heidelberg, Ger-
many). Cells were cultured according to the instructions of
the producer using endothelial cell growth medium MV
(PromoCell). Normal human bronchial epithelial cells
(NHBE) were obtained from Clonetics (CellSystems,
St. Katharinen, Germany) and cultured in BEGM medium
according to the instructions of the producer. Human foreskin
fibroblasts (HFF) and retinal glial cells (HRG) were isolated
and cultivated as described previously using IMDM supple-
mented with 10% FBS, 100 IU/ml penicillin, and 100 mg/ml
streptomycin [24]. The human alveolar rhabdomyosarcoma
(ARMS) cell line, KFR, was established in our laboratory
from bone marrow metastases of a patient suffering from
ARMS [25]. KFR cells were grown in IMDM supplemented
with 10% FCS, 100 IU/ml penicillin, and 100 mg/ml strepto-
mycin. Cells were routinely tested for Mycoplasma and
found to be free of contamination.
Oncolysis of Human Cultured Cells
For in vitro susceptibility assays, cultured cells were
plated in six-well dishes at a density of 5  104 cells/cm2.
After 72 hours, confluent cell layers were infected with G207
at an MOI of 0.1, or mock-infected with viral buffer alone.
After an adsorption period (90 minutes) at 37jC, infected
cells were maintained in growth medium containing 1% heat-
inactivated FCS at 37jC. Viable cells were counted in a
hemocytometer using the trypan blue exclusion method
at different times postinfection.
In some experiments, endothelial cells were treated with
inhibitors of RR including DFO (6.25–100 mM concentra-
tions) and hydroxyurea (125–1000 mM), or inhibitors of Ras/
Raf/MEK/Erk cascade including farnesyltransferase inhibitor
manumycin A (5–40 mM) and MEK inhibitor PD98059 (5–40
mM). The inhibitors were added 2 hours before infection.
Immunoblotting
Cells were lysed in sodium dodecyl sulfate (SDS) sample
buffer and separated by SDS-PAGE, as described previ-
ously [23]. In brief, proteins were detected using specific
antibodies against Erk1/2 and its phoshorylated form, phos-
phoro-Erk1/2 (Cell Signaling, Beverly, MA), actin (Sigma), or
M1 subunit of human RR (Biomol, Hamburg, Germany),
and were visualized by enhanced chemiluminescence using
a commercially available kit (Amersham, Braunschweig,
Germany).
Infection Efficiency and Viral Growth of HSV-1 G207 in
Cultured Cells
To evaluate the infection efficiency of G207 in different
cell cultures, X-gal (Sigma) staining was performed using a
previously described technique [11]. The percentage of lacZ-
positive cells was calculated as a measure of infection 3 days
after infection. To assess the replication capacity of virus,
viral titers were measured in different cell types. Cells were
incubated with G207 at an MOI of 0.1 for an adsorption
period (90 minutes) and washed three times with PBS, and
maintenance medium was added. Immediately after virus
adsorption (input virus titer) or different times postinfection,
cultures were subjected to three cycles of freeze–thaw lysis,
sonication, and centrifugation at 2000g for 10 minutes at
4jC. Infectious titers of supernatants were determined on
confluent Vero cell layers, as described above.
In Vitro Matrigel Angiogenesis Assay
The assay was performed as described previously
[23]. Briefly, 96-well plates were coated with cold Matrigel
(50 ml/well), which was allowed to polymerize at room tem-
perature for about 30 minutes. HUVEC were mock-infected,
infected with G207, or infected with UVB-inactivated G207.
After 1 hour of adsorption and infection, cells were washed
and 100 ml of a suspension of differently treated HUVEC
(5  104 cells/ml) was seeded onto Matrigel in IMDM, sup-
plemented with 100 IU/ml penicillin, 100 mg/ml streptomycin,
1% (vol/vol) FCS, and 5 ng/ml bFGF. In some experiments,
acyclovir at a concentration of 20 mM was added to cultures
of G207-infected cells. Tube formation was assessed after
48 hours and quantified by counting of branching points.
In Vivo Matrigel Plug Assay
All animal experiments were performed according to the
guidelines for the use of vertebrate animals of the Charles
University (Prague, Czech Republic). C57/BL6 mice (AnLab
Ltd., Prague, Czech Republic) were used for Matrigel plug
assay. Matrigel (0.5 ml) supplemented with 75 ng bFGF
was injected subcutaneously into the flank. Solvent (saline),
G207, or UVB-inactivated G207 (all in a volume of 50 ml) was
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injected into the plug on days 1 and 3 after Matrigel injection.
On day 10, animals were sacrificed, and the Matrigel plug
together with surrounding tissue were removed. The tissue
was fixed overnight in phosphate-buffered saline containing
10% formalin and 0.25% glutaraldehyde, embedded into
paraffin, and stained with Masson’s trichrome, as described
previously [23]. This procedure stains the Matrigel blue and
endothelial cells/vessels red. To quantify the extent of an-
giogenesis, perfused blood vessels were counted.
Subcutaneous Xenotransplanted Tumor Model of Human
Rhabdomyosarcoma
Female outbred athymic nude mice, strain CD-1 (nu/nu),
about 20 g of weight (AnLab Ltd., Charles River, Czech
Republic), were used for experiments. Mice were kept under
sterile conditions, receiving sterile nutrition and water. A total
of 1  107 human KFR cells were injected subcutaneously
together with Matrigel in a total volume of 0.2 ml into the right
flank of mice. Tumor volumes were determined using a
caliper and calculated by the formula: Volume = (length 
width2)/2. The longer side was defined to be the length and
the shorter one was defined to be the width.
Intraneoplastic Treatment of Human Rhabdomyosarcoma
Tumors with HSV-1 G207
Xenotransplanted KFR tumors were established as de-
scribed above. After tumor cell inoculation, mice were ran-
domly divided into groups of seven animals. When tumors
reached a size of about 100 mm3, treatment was started.
This day was defined to be day 0. Animals received 1  107
plaque-forming units (PFU) G207 intratumorally, suspended
in a volume of 20 ml of virus buffer on days 0 and 4. Con-
trol animals received intratumoral virus buffer or UVB-
inactivated G207 virus suspension.
Immunohistochemical Analysis
To detect endothelial cells in tumor tissues, immunohis-
tochemical analysis of subcutaneous KFR tumors treated
with saline (control) or G207-treated tumors was per-
formed. Tumors excised from sacrificed animals were rinsed
with sterile PBS, fixed in 10% neutral-buffered formalin,
embedded into paraffin, and sectioned. Thin sections were
examined with immunoperoxidase, carried out using a rab-
bit anti –mouse Factor VIII antiserum (DakoCytomation,
Hamburg, Germany). Slides were then subjected to avidin–
biotin–horseradish peroxidase staining and counterstained
in hematoxylin. The numbers of Factor VIII–stained vessels
were counted by two independent observers in tumor tissue
areas, which included higher vessel density (hot spot).
Reverse Transcription Polymerase Chain Reaction
(RT-PCR)
Total RNA was isolated from HUVEC (mock- and G207-
infected, with or without DFO treatment) using TRIZOL
according to the manufacturer’s instructions (Gibco-BRL Life
Technologies, Gaithersburg, MD). RNA was reverse-tran-
scribed using random hexamer priming, as described previ-
ously [26]. mRNA levels of the viral genes a (a27), b (UL30),
and g (UL44) were detected using the following primers [27]:
for a27, 5V-CTGGAATCGGACAGCAGCCGG-3V and 5V-
GAGGCGCGACCACACACTGT-3V, which yield a 222-bp
fragment; for UL30, 5V-ATCAACTTCGACTGGCCCTTC-3V
and 5V-CCGTACATGTCGATGTTCACC-3V, producing a
180-bp fragment; and for UL44, 5V-GCCGCCGCCTAC-
TACCC-3V and 5V-GCTGCCGCGACTGTGATG-3V, amplify-
ing a 661-bp fragment. The sequence of GAPDH primers
used as control was as follows 5V-TGGGGAAGGT-
GAAGGTCGGA-3V and 5V-GAAGGGGTCATTGATGGCAA-
3V [26]. PCR amplification of the cDNA was carried out by
adding 0.5 mg of Taq DNA polymerase (Roche, Mannheim,
Germany). PCR amplification of fragments was performed
using 28 cycles in a DNA thermocycler using the following
conditions: denaturation for 1 minute at 94jC, annealing for
2 minutes at 60jC, and extension for 2 minutes at 72jC,
whereas conditions for amplification of GAPDH fragment
were as follows: denaturation for 1 minute at 94jC, annealing
for 1 minute at 52jC, and extension for 1.5 minutes at 72jC
in a Perkin Elmer Thermocycler (Rodgau-Ju¨gesheim, Ger-
many). PCR products were resolved alongside DNA marker
on an agarose gel, stained with ethidium bromide, and
photographed.
Electron Microscopy
For ultrastructural investigations of viral infection, mice
bearing KFR tumors treated with G207 as described above
were sacrificed on day 2 of treatment. Electron microscopy
was performed as described previously [11]. Tumor speci-
mens were fixed in 4% formalin and 1% glutaraldehyde in
monobasic phosphate buffer (pH 7.2), postfixed in 1% osmi-
um tetroxide, dehydrated in ethanol, and imbedded in Durcu-
pan Fluka (Sigma). Thin sections were contrasted with uranyl
acetate and lead citrate, and viewed with a Jeol JEM, 2000
CX microscope (Jeol Europe, Prague, Czech Republic).
Statistics
Statistical analysis was performed using Jandel Sigma-
Stat 2.0 (Jandel Scientific, Erkrath, Germany). Comparison
between two groups was performed using Student’s t test;
three or more groups were compared by analysis of variance
followed by Tukey test. P values less than .05 were consid-
ered significant.
Results
Susceptibility of Human Endothelial Cells to HSV-1 G207
In Vitro
The oncolytic activity of G207 was assessed in vitro in
confluent HUVEC and HDMEC layers. The oncolytic activ-
ity of G207 in endothelial cells was compared with the
effects of G207 on KFR rhabdomyosarcoma cell line and
nontransformed human fibroblasts HFF. G207 exerted a
direct time-dependent cytopathic effect on both endothelial
cell lines. G207 infection caused cell death of 100% of
HUVEC or HDMEC 3 days postinfection at an MOI of 0.1.
In rhabdomyosarcoma KFR cultures, about 22% of cells
survived 3 days postinfection. In contrast to this, G207 did
G207 Inhibits Angiogenesis Cinatl et al. 727
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not influence the number of viable cells in HFF, NHBE, and
HRG cultures (Figure 1). Wild-type HSV-1 strain McIntyre,
an HSV-1 strain that has comparable cytopathic activity as
an HSV-1 strain F (i.e., the parental strain of HSV-1 G207)
[28], caused cell death to a similar extent in both normal and
tumor cells (Figure 1). Furthermore, using three different
HSV-1 isolates from patients yielded results comparable to
HSV-1 strain McIntyre (data not shown).
Infection Efficiency and Viral Growth in Human Endothelial
Cells
The efficiency of G207 infection and replication in endo-
thelial cell cultures was demonstrated by lacZ expression
(i.e., green-stained cells) and measurement of virus titer in
infected cultures. At the time point of infection, HUVEC were
all in cell cycle phase G1. Figure 2A shows representative
pictures of HUVEC cultures 24 and 72 hours postinfection.
Virus-induced cytopathogenic effects forming distinct pla-
ques of rounded cells were detected 24 hours after infection.
LacZ staining demonstrated 10% to 15% of lacZ-positive
cells in the G207-infected cells after 24 hours. Strongly
enhanced cytopathogenic effects were detected 3 days
postinfection: cells rounded and detached from cell culture
surface. More than 99% of cells stained positively for lacZ
(Figure 2A). Increasing numbers of lacZ-positive cells corre-
lated with increasing G207 infectious titers. Three days
postinfection, HUVEC and HDMEC produced 4.1  107
and 9.8  106 PFU/ml, respectively (Figure 1). The sensitiv-
ity of HUVEC was confirmed by transmission electron mi-
croscopy demonstrating naked nucleocapsids as well as
enveloped viral particles in infected cells (Figure 2B).
In KFR cultures, about 75% of cells were positive for lacZ.
Viral titers also increased in a time-dependent manner.
However, the viral titer, being 5.4  105 PFU/ml 3 days
postinfection, was much lower than in endothelial cells
(Figure 1). HFF, HBE, and HRG did not stain positively for
lacZ 3 days postinfection. No infectious virus was measur-
able in HFF, HBE, and HRG (Figure 1). The increase of cell
killing in all types of normal and tumor cells infected with
HSV-1 wild-type strain McIntyre was associated with in-
creased viral titers (Figure 1).
G207 was attenuated by inactivation of the ICP6 gene
encoding viral RR and deletion of the c34.5 gene that is one
of the major determinants of HSV-1 neurovirulence [14]. The
c34.5 gene deletion can be somewhat compensated by
cellular Ras overexpression [27]. Therefore, inhibitors of
Ras/Raf/MEK/Erk cascade and RR were used to investigate
if these were able to inhibit G207 replication in HUVEC. Both
manumycin A, an inhibitor of farnesyltransferases that inhib-
its activation of Ras [29], and the MEK inhibitor PD98059 [30]
were used at concentrations that led to reduced phosphoryl-
ated Erk in HUVEC that presented a constitutively activated
Ras pathway (Figure 3A). However, even at the highest
concentrations used, both inhibitors did not influence infec-
tion efficiency as determined by the number of lacZ-express-
ing cells or cell killing (data not shown). Interestingly, HUVEC
Figure 2. Induction of cytopathogenic effect and expression of lacZ in infected HUVEC 24 and 72 hours postinfection. Arrows show G207-induced cell rounding in
native cultures as well as lacZ-positive (infected) cells in cultures stained with X-gal (A). Transmission electron microscopy of cytoplasm (c) and parts of nuclei (n)
of HUVEC cells showing enveloped viral particles (arrow) in the cytoplasm 48 hours postinfection (B).
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express RR at a comparable level as KFR rhabdomyosar-
coma cells, whereas HFF presented only inferior levels of RR
protein (Figure 3B). In contrast to the mentioned Ras inhib-
itors, the RR inhibitor, desferrioxamine (DFO) [31], inhibited
G207 replication dose-dependently between concentrations
of 6.25 and 100 mM. A concentration of 100 mM completely
inhibited virus infection and prevented virus-induced cell
killing (Figure 4A). DFO treatment of mock-infected confluent
HUVEC had no significant effect on cell viability. The RR
inhibitor, hydroxyurea [32], inhibited G207 replication in a
similar manner (not shown).
To investigate at which phase of G207 replicative cycle
DFO inhibits virus infection, the effects of DFO (100 mM,
added 2 hours before virus infection) on mRNA levels of
different classes of viral a, b, and g gene transcripts were
observed. The transcripts of the immediate early gene a27,
which is required for the subsequent production of b and g
genes [33], were present in comparable levels in both DFO-
treated and untreated (control) HUVEC 4 hours postinfec-
tion. The b-gene transcripts were present at much lower
levels in DFO-treated cells than in infected control cultures
24 hours postinfection. UL44 g2 gene transcripts, which are
defined as requiring the onset of viral DNA synthesis genes
[33], were not detected in DFO-treated cells infected with
G207 24 hours postinfection (Figure 4B).
Effect of G207 on Angiogenesis In Vitro
A crucial step during angiogenesis is the organization of
endothelial cells into functional vessels. This process is
simulated in vitro by the tube formation assay. Mock-infected
HUVEC plated on extracellular matrix (Matrigel) formed a
network of tube-like structures (Figure 5A). In contrast to this,
tube-like structures were destroyed in cultures infected with
G207 at an MOI of 0.1, 48 hours after seeding on Matrigel,
but dead cells were organized in net-like structures compa-
rable to normal tube formation indicating viral oncolysis
mediated by G207 at the moment of active tube formation
(Figure 5A). UVB-inactivated G207 did not destroy tube-like
structures. Addition of acyclovir (20 mM) prevented the
destruction of tube-like structures by G207. This shows that
viral replication and endothelial cell lysis are essential for the
destruction of tube-like structures.
Effect of G207 on Angiogenesis In Vivo
To evaluate antiangiogenic effects of G207 in vivo, a
Matrigel plug assay was performed. Matrigel plugs supple-
mented with bFGF were introduced subcutaneously into
mice. The plugs are supposed to contain vessels as soon
as day 4 after implantation [34]. A total of 1  107 PFU G207
was injected into the Matrigel plug on days 1 and 3. On day
10, Matrigel plugs were removed, stained with Masson’s
trichrome, and investigated for endothelial cell invasion and
vessel formation [35]. Plugs from control mice treated with
virus buffer showed a strong invasion of endothelial cells and
the formation of perfused vessels (Figure 5B). In contrast to
this, plugs from G207-treated animals only showed weak
invasion of endothelial cells. To investigate, if virus replica-
tion was necessary for antiangiogenic effects, UVB-inacti-
vated G207 was injected into the plugs on days 1 and 3.
Injection of inactive virus resulted in endothelial cell invasion
and vessel formation comparable to control.
Replication of G207 in Tumor and Endothelial Cells
Previously, we demonstrated that intratumoral treatment
of KFR tumors in nude mice inhibited tumor growth due to
virus replication and spreading in tumor cells [11]. Consistent
with these results, Figure 6A shows that intratumoral treat-
ment with G207 inhibited KFR tumor growth in all animals
and induced complete tumor disappearance in four of seven.
Eight days after virus injection, histochemical examination
of control tumors showed a morphology that is typical for
ARMS, with many perfused microcapillaries (in the hotspot
sites of tumors, 18 ± 4.2 vessels were detected), whereas
G207-treated tumors were composed of necrotic cells with-
out any microcapillaries (Figure 6B). To show whether G207
may infect endothelial cells, G207-treated tumors were ex-
amined by electron microscopy. Ultrastructural investiga-
tions showed viral particles in tumor and endothelial cells
of treated xenografts (Figure 6C), but not in adjacent normal
tissues 24 hours after G207 injection (not shown).
Figure 3. Investigation of Ras pathway in HUVEC (A) and RR expression in
different cell types. (B) HUVEC were exposed with the faranesyltransferase
inhibitor, manumycin A, and MEK inhibitor, PD98059. Inhibitory effects of
manumycin A on faranesyltransferase activity and PD98059 on MEK1/2
activity were indicated by the lack of Erk1/2 phosphorylation. (A) Protein
expression profiles of cellular ribonucleotide reductase (RR, subunit M1) were
observed in HFF, HUVEC, and KFR cell lines (B).
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Discussion
In the present study, we showed for the first time that an
oncolytic virus inhibits angiogenesis. In addition, this is the
first report that demonstrates the productive infection of
endothelial cells from different origins by the oncolytic virus,
HSV-1 G207. UVB irradiation of viral particles or treatment
with antiviral agent acyclovir prevented the inhibition of
in vitro tube formation and vessel formation in the in vivo
Matrigel assay induced by G207 infection. These results
show that viral replication is essential for antiangiogenic
effects of G207.
The finding that G207 replicates in confluent endothelial
cell cultures is somewhat surprising because the multimu-
tated oncolytic virus was designed to selectively replicate in
dividing transformed cells. In fact, human normal (nontrans-
formed) cells including dermal fibroblasts, bronchial epithe-
lial cells, and HRG did not promote replication of G207 as
demonstrated by the failure to produce infectious virus and to
Figure 4. Infection efficiency and cell killing of HUVEC treated with DFO at concentrations ranging from 6.25 to 100 M. DFO was added to cell cultures 2 hours
before virus infection. Infection efficiency was examined 72 hours postinfection by calculation of the percentage of lacZ-positive cells, and viable cells were counted
using the trypan blue exclusion method. Each data point (mean of triplicate wells ± SD) is the percentage of cells expressing -galactosidase or surviving cells
compared with mock-infected cells in control wells, respectively (A). Effects of DFO (100 M, added 2 hours before virus infection) on G207 replicative cycle in
HUVEC. Cells were collected and cytoplasmatic RNA was extracted at 4 and 24 hours after virus infection. mRNA levels of HSV-1–specific a-gene (a27) were
detected 4 hours after virus infection, whereas -gene (UL30) and g-gene (UL44) were measured 24 hours after virus infection. RT-PCR products were separated
on a 1.5% agarose gel and visualized with ethidium bromide under ultraviolet light (B).
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destroy cells in infected cultures. However, these normal cell
types were highly sensitive to replicative and cytotoxic
effects of wild-type HSV-1. Therefore, unlike other normal
cell types, endothelial cells seem to be unique in their
susceptibility to G207.
G207 is derived from HSV-1 mutant R3616, which con-
tains deletions in both loci of the c34.5 gene that is required
for replication in the central nervous system [12,13]. HSV-1
infection leads to the activation of double-stranded RNA-
activated protein kinase (PKR). PKR causes phosphoryl-
ation and therefore inactivation of the a-subunit of eukaryotic
translation initiation factor 2 (eIF2a), leading to inhibition of
cellular translation [36]. The gene product of g134.5 (called
ICP34.5) presumably forms a complex with protein phos-
phatase 1 (PP1), leading to dephosphorylation/activation of
eIF2a and restoring cellular translation in HSV-1–infected
cells [37]. Thus, the absence of ICP34.5 results in the
inhibition of translation of the viral transcripts in normal
(nontransformed) cells. Ras-transfected cells are able to
compensate for the lack of ICP34.5 and are permissive to
infection, with HSV-1 mutants lacking the c34.5 gene [27].
Because Ras is constitutively activated in a high number of
different tumors [38], destruction of the c134.5 gene limits
specific virus replication to Ras-overexpressing tumor cells.
Ras leads to inhibition of PKR phosphorylation/activation
and, in turn, to phosphorylation/inactivation of eIF2a. Treat-
ment of Ras-overexpressing cells with a farnesyl transferase
inhibitor that inhibits the activation of Ras or PD98059, an
inhibitor of the downstream signal protein of Ras MEK,
inhibited HSV-1 R3616 replication in Ras-overexpressing
cells to some extent [27]. This shows that the inhibition of
PKR phosphorylation by Ras overexpression is, at least in
part, mediated by the Ras/Raf/MEK cascade. To evaluate
the importance of the Ras/Raf/MEK cascade for replication
of G207 in endothelial cells, endothelial cells were infected
with G207 in the presence of the farnesyltransferase inhib-
itor, manumycin A, or the MEK inhibitor, PD98059. Neither
manumycin A nor PD98059 exhibited significant effects on
G207 replication or cell killing in infected endothelial cultures,
despite the fact that both inhibitors reduced significantly the
Figure 5. Effects on angiogenesis in vitro (A) and in vivo (B). Infection of HUVEC at an MOI of 0.1 significantly suppressed in vitro tube-like formation (P < .001),
whereas the effects were not observed after treatment with acyclovir (20 M) or infection with G207 inactivated by UVB (A). G207 significantly prevented the
formation of perfused vessels in the in vivo Matrigel plug assay (P < .001). In contrast, similar numbers of perfused vessels were observed in Matrigel plugs after
mock infection or infection with UVB-irradiated G207 (B).
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level of phosphorylated Erk in treated HUVEC. Thus, we
suggest that the Ras pathway does not play an essential role
for replication of G207 in endothelial cells.
To further ensure that G207 is unable to replicate in
normal quiescent cells, the viral ICP6 gene, encoding the
large subunit of viral RR (the enzyme that reduces ribonu-
cleotides to deoxyribonucleotides necessary for DNA syn-
thesis), was inactivated in G207 [14]. This genetic
modification renders the replication of G207 dependent on
the presence of cellular RR. Dividing normal cells that
express high levels of cellular RR activity can be destroyed
by HSV-1 strains lacking RR. Oncolytic HSV-1 strain hrR3
with inactivated RR gene was shown to infect and selectively
kill actively proliferating rat retinal pigment epithelial cells
while sparing normal nonreplicating cells [39]. Moreover,
upregulation of RR by ionizing radiation potentiated G207
replication. Chemical RR inhibition using hydroxyurea abro-
gated enhanced replication again [40]. In concordance with
these findings, nonreplicating confluent HFF that are per-
missive to infection by wild-type HSV-1 were nonpermissive
to G207. Confluent endothelial cells, however, were highly
permissive to G207 infection. HUVEC and KFR rhabdomyo-
sarcoma cells express high levels of RR in comparison to
HFF cells. Addition of two RR inhibitors, namely DFO and
hydroxyurea, prior to virus infection resulted in a dose-
dependent suppression of G207 replication in HUVEC. In-
vestigation of mRNA levels of viral genes expressed at
different phases of viral replication cycle revealed that RR
inhibitors inhibited G207 replication but did not influence viral
adsorption and penetration. This suggests that cellular RR
activity, in accordance with other studies, is most probably
responsible for G207 replication in confluent endothelial cells
[4,40–42].
In addition to the effects on endothelial cells, our present
study confirmed previous results demonstrating that G207
infects and destroys KFR cells in vitro and inhibits growth of
KFR xenografts in mice [11]. The sensitivity of KFR cells to
G207 infection complicates the rating of the impact of G207-
caused angiogenesis inhibition on tumor development in this
model. Nevertheless, the complete absence of tumor ves-
sels in G207-treated tumors and the detection of virus
particles in tumor endothelial cells clearly demonstrate the
inhibition of tumor angiogenesis by G207. Further investiga-
tions will have to study the influence of G207 on growth and
vessel formation of tumors, which are nonpermissive to
G207. It is also important to compare the sensitivity of
Figure 6. Xenografts of subcutaneous KFR tumors treated with intrathecal. G207. Growth curves of control (saline-treated) and G207-treated established KFR
tumors after the start of treatment (A). Examination of thin sections stained with H&E show tumor vessels filled with erythrocytes (arrows) and immunoperoxidase
staining with anti –mouse Factor VIII antiserum depicts endothelial cells of tumor microvessels (arrows). Endothelial cells were not detected in tumors 8 days after
G207 injection (B). Detection of G207 in endothelial cells of KFR xenografts 24 hours after G207 treatment. Enveloped viral particles are frequently enclosed in
vacuoles in the cytoplasm of endothelial cells, which are shown in greater magnification in insets. Furthermore, enveloped viral particles in the cytoplasm and
nucleocapsids in nucleus are shown in a tumor cell (C). EC = endothelial cell; TC = tumor cell; n = nucleus; c = cytoplasm.
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tumor-associated endothelial cells to G207 with that of the
normal endothelium of different organs. Although this item
was not addressed in the present study, ultrastructural
investigations failed to demonstrated G207 particles in ad-
jacent normal tissues. Moreover, previous animal studies
showed that G207 does not disseminate and replicate in
normal cells of different organs [11,43,44].
Angiogenesis is considered to play a central role in tumor
growth and metastasis formation. Numerous antiangiogenic
agents are under clinical evaluation in phase II and phase III
trials [22,45]. Oncolytic viruses such as G207 represent an
interesting new therapeutical approach to suppress tumor
angiogenesis because their mode of action differs from that
of other antiangiogenic drugs. New investigations indicated
that clinical use of angiogenesis inhibitors is more compli-
cated as initially expected. Therefore, establishment of prop-
er treatment schedules and a combination of different
antiangiogenic agents is regarded as necessary to achieve
efficient angiogenesis inhibition and, consequently, antican-
cer activity in patients [22]. G207 appears to be a very well-
suited additional tool for angiogenesis inhibition, alone or in
combination with other antiangiogenic agents or therapy
strategies. We have already demonstrated that combination
with vincristine drastically enhanced the anticancer activity of
G207 in a xenotransplanted rhabdomyosarcoma model [11].
Similarly, increased cell killing of a human non small cell lung
cancer cell line treated with the combination of oncolytic
HSV-1 1716 and mitomycin C has been demonstrated [46].
Because nontoxic frequent low dosing of cytotoxic agents
was shown to suppress tumor growth by inhibition of angio-
genesis in several experimental models, the combination of
G207 with cytotoxic drugs should be investigated as a new
antiangiogenic strategy [21,22].
In conclusion, this report shows that infection with onco-
lytic HSV-1 G207 inhibits angiogenesis, including tumor-
induced vessel formation. Viral replication in endothelial cells
is necessary for the inhibition of angiogenesis. The antian-
giogenic mechanism of G207 differs from that of all known
antiangiogenic agents under evaluation. Our study provides
new insights into the antitumoral function of oncolytic G207
and opens a new field of therapeutic concepts that should be
combined with G207 against cancer in humans.
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